Developed in the late 1990s/early 2000s as a focused hGH fragment, AOD-9604 was advanced into early clinical programs to investigate mechanism-driven metabolic effects and safety. Subsequent summaries report randomized, placebo-controlled trials evaluating IGF-1, glucose tolerance, and immunogenicity endpoints in research settings.
Peptides
AOD9604
$55.00
AOD-9604 is a synthetic peptide fragment derived from the C-terminus of the somatotropin sequence (fragment 176–191, with an added N-terminal Tyr). It is studied for its effects on lipolytic and anti-lipogenic pathways, β3-adrenergic signaling, and downstream pathway dynamics in laboratory and preclinical models.




Reviews
There are no reviews yet.